Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Article Details

Citation
Copy to clipboard

Totah RA, Rettie AE

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Clin Pharmacol Ther. 2005 May;77(5):341-52. doi: 10.1016/j.clpt.2004.12.267.

PubMed ID
15900280 [ View in PubMed
]
Abstract

Cytochrome P450 (CYP) 2C8 [corrected] has been a relatively neglected member of the human CYP2C family. Over the period from 2000 through 2003, PubMed searches with the key word CYP2C8 returned only 10% to 15% of the citations obtained for all of the CYP2C enzymes combined. However, in the past year a crystal structure for CYP2C8 has been described, new inhibitors and probe substrates for the enzyme have been in development, the first case study was published linking CYP2C8 genetic polymorphisms to a disease state, and there has been an increasing awareness of the role that CYP2C8 plays in the disposition of therapeutic agents, especially from the pharmacogenetic and drug-drug interaction perspectives. This report discusses baseline characteristics of the enzyme and summarizes recent developments in these areas and their clinical relevance.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
VerapamilCytochrome P450 2C8ProteinHumans
Unknown
Substrate
Inhibitor
Details
Drug Interactions
DrugsInteraction
Integrate drug-drug
interactions in your software
Almotriptan
Secobarbital		The metabolism of Almotriptan can be increased when combined with Secobarbital.
Almotriptan
Bexarotene		The metabolism of Almotriptan can be decreased when combined with Bexarotene.
Almotriptan
Loratadine		The metabolism of Almotriptan can be decreased when combined with Loratadine.
Almotriptan
Medroxyprogesterone acetate		The metabolism of Almotriptan can be decreased when combined with Medroxyprogesterone acetate.
Almotriptan
Irbesartan		The metabolism of Almotriptan can be decreased when combined with Irbesartan.